Skip to content
10-K

Annual Report

DIAMEDICA THERAPEUTICS INC. DMAC

0001437749-26-010342

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 53.88M sh
Capex FY 2025 · Dec 31, 2025 $40K
Capex FY 2025 · Dec 31, 2024 $25K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$29.06M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$22.08M
Cash And Equivalents FY 2025 · Dec 31, 2025 $15.65M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.03M
Stockholders Equity FY 2025 · Dec 31, 2025 $56.11M
Stockholders Equity FY 2025 · Dec 31, 2024 $40.72M
Stockholders Equity FY 2025 · Dec 31, 2023 $51.06M
Current Liabilities FY 2025 · Dec 31, 2025 $5.13M
Current Liabilities FY 2025 · Dec 31, 2024 $5.39M
Current Assets FY 2025 · Dec 31, 2025 $60.63M
Current Assets FY 2025 · Dec 31, 2024 $44.61M
Total Assets FY 2025 · Dec 31, 2025 $61.37M
Total Assets FY 2025 · Dec 31, 2024 $46.35M
Eps Basic FY 2025 · Dec 31, 2025 −$0.70
Eps Basic FY 2025 · Dec 31, 2024 −$0.60
Sga Expense FY 2025 · Dec 31, 2025 $9.78M
Sga Expense FY 2025 · Dec 31, 2024 $7.62M
Rd Expense FY 2025 · Dec 31, 2025 $24.61M
Rd Expense FY 2025 · Dec 31, 2024 $19.06M
Net Income FY 2025 · Dec 31, 2025 −$32.77M
Net Income FY 2025 · Dec 31, 2024 −$24.44M
Operating Income FY 2025 · Dec 31, 2025 −$34.4M
Operating Income FY 2025 · Dec 31, 2024 −$26.68M